Answers are grounded in this paper and cite their sources.
Prostate cancer remains the most common type of cancer among men in the United States. Treatment for metastatic prostate cancer has improved significantly over the years with more and more agents improving overall survival. This review will address the pathophysiology of prostate cancer followed by the mechanism of action and the pharmacokinetic properties of abiraterone. The review will also discuss the role of abiraterone in the treatment of metastatic castrate-resistant prostate cancer.
No takes yet. Share an insight, caveat, or question.
Fong et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: